Patents by Inventor Yusuke Tomita

Yusuke Tomita has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10434407
    Abstract: Provided is a game system capable of imposing restriction upon the beneficial effects of the characteristics of a character that has been selected. This game system is provided with control panels having individual rotational buttons. The game system provides a music game in which operation timings at which the individual rotational buttons are to be operated are guided in accordance with the rhythm of a musical piece selected from a musical piece group. Furthermore, the game system awards card selection opportunities for selecting character cards to be used in play, from a plurality of character cards prepared so as to have a plurality of skills which are different to each other, and which respectively correspond to changes. In a special mode, the game system sequentially implements, in a prescribed order every time the special mode is offered, the changes corresponding to the skills of the respective selected character cards.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: October 8, 2019
    Assignee: KONAMI DIGITAL ENTERTAINMENT CO., LTD.
    Inventors: Masahiro Kiyomoto, Koichi Tomita, Toyokazu Sakai, Shohei Sakuraba, Erina Takeda, Toru Miki, Atsushi Usami, Kanae Kokutani, Naotaka Okamoto, Yusuke Kobayashi
  • Publication number: 20190264984
    Abstract: A stacked heat exchanger includes: passage tubes stacked with each other to support a heat exchange object, a passage being defined in the passage tube for a heat medium to exchange heat with the heat exchange object; and a pipe connected to one of the passage tubes located at one end in a stacking direction of the plurality of passage tubes. Each of the passage tubes has a protruding pipe portion protruding in the stacking direction and communicating with the adjacent passage tube in the stacking direction. The one of the passage tubes located at the one end in the stacking direction is an in/out passage tube. The pipe has a surface at one end in a longitudinal direction of the pipe, and the surface intersects the longitudinal direction of the pipe and is joined to the in/out passage tube.
    Type: Application
    Filed: May 9, 2019
    Publication date: August 29, 2019
    Inventors: Yusuke TAKAGI, Ryohei TOMITA, Shingo OONO
  • Publication number: 20190264774
    Abstract: A damper device includes a damper device body, an output shaft and a dynamic vibration absorber. The damper device body includes an input member and an output member. The input member and the output member are coupled to be rotatable relative to each other. The output shaft outputs a torque transmitted to it from the damper device body. The dynamic vibration absorber is attached to the output shaft.
    Type: Application
    Filed: October 23, 2017
    Publication date: August 29, 2019
    Inventors: Yuki KAWAHARA, Yusuke TOMITA
  • Publication number: 20190257383
    Abstract: A vibration reduction device for reducing a torsional vibration from an engine includes an input rotary part, an output rotary part, a damper part, a dynamic vibration absorbing device, and a torque limiting part. Torsional vibration is input to the input rotary part. The output rotary part is disposed to be relatively rotatable with respect to the input rotary part. The damper part is disposed between the input rotary part and the output rotary part and attenuates the torsional vibration input to the input rotary part. The dynamic vibration absorbing device absorbs the torsional vibration output from the damper part. The torque limiting part limits transmission of torque between the input rotary part and the output rotary part.
    Type: Application
    Filed: July 27, 2017
    Publication date: August 22, 2019
    Applicant: EXEDY Corporation
    Inventors: Yuki KAWAHARA, Yusuke TOMITA, Yusuke OKAMOTO
  • Publication number: 20190257385
    Abstract: A torque fluctuation inhibiting device configured to inhibit torque fluctuations is disclosed. The torque fluctuation inhibiting device comprises a first rotor, a second rotor disposed to be rotatable relative to the first rotor, a centrifugal element, and a cam mechanism. The centrifugal element is configured to receive a centrifugal force generated by rotation of the first rotor. The centrifugal element is disposed to be movable with respect to the first rotor. The centrifugal element includes an engaging portion configured to be engage with the first rotor. The centrifugal element is formed by a plurality of components. The cam mechanism is configured to generate a circumferential force in movement of the centrifugal element and the circumferential force reduces relative displacement between the first rotor and the second rotor.
    Type: Application
    Filed: February 12, 2019
    Publication date: August 22, 2019
    Inventors: Yusuke TOMITA, Tomohiro WADA
  • Publication number: 20190226553
    Abstract: A torque fluctuation inhibiting device for inhibiting torque fluctuations in a rotor to which a torque is inputted is disclosed. The torque fluctuation inhibiting device comprises a mass body, a plurality of drag mechanisms, and a restriction mechanism. The mass body is disposed to be rotatable with the rotor and to be rotatable relative to the rotor. Each of the plurality of drag mechanisms is for generating a circumferential force when a relative displacement is produced between the rotor and the mass body in a rotational direction. The circumferential force is directed to reduce the relative displacement. The restriction mechanism is for restricting actuation of one or more of the plurality of drag mechanisms.
    Type: Application
    Filed: December 12, 2018
    Publication date: July 25, 2019
    Applicant: EXEDY Corporation
    Inventor: Yusuke TOMITA
  • Publication number: 20190186593
    Abstract: A torque fluctuation inhibiting device includes a first rotating body, a second rotating body, a centrifugal element, a support portion, and a displacement inhibiting mechanism. Torque is input to the first rotating body. The centrifugal element is subject to centrifugal force due to rotation of the first rotating body and moves in a direction different from a direction in which the centrifugal force acts. The support portion is provided in the first rotating body or the second rotating body and moveably guides the centrifugal element in the direction different from the direction in which the centrifugal force acts on the centrifugal element. The displacement inhibiting mechanism generates circumferential force which reduces a relative displacement of the first rotating body and the second rotating body when the centrifugal element moves in the direction different from the direction in which the centrifugal force acts on the centrifugal element.
    Type: Application
    Filed: December 10, 2018
    Publication date: June 20, 2019
    Inventors: Yuki KAWAHARA, Naoki TOMIYAMA, Yusuke TOMITA
  • Publication number: 20190145491
    Abstract: A vibration reduction device for reducing a torsional vibration from an engine includes an input rotary part, an output rotary part, a damper part, a dynamic vibration absorbing device, and a hysteresis torque generating part. The torsional vibration is input to the input rotary part. The output rotary part is disposed to be relatively rotatable with respect to the input rotary part. The damper part is disposed between the input rotary part and the output rotary part and attenuates the torsional vibration input to the input rotary part. The dynamic vibration absorbing device is for absorbing the torsional vibration output from the damper part. The hysteresis torque generating part is capable of generating a hysteresis torque when the damper part is in operation.
    Type: Application
    Filed: July 27, 2017
    Publication date: May 16, 2019
    Inventors: Yusuke TOMITA, Yuki KAWAHARA, Yusuke OKAMOTO
  • Publication number: 20190085936
    Abstract: A torque fluctuation inhibiting device includes plural centrifugal elements movable in a radial direction when receiving a centrifugal force generated in rotation of a rotor and a mass body. Each centrifugal element receives a rotational moment of inertia about an axis arranged in parallel to a rotational axis of the rotor when receiving the centrifugal force. When a relative displacement is produced between the rotor and the mass body in a rotational direction due to the centrifugal force acting on each centrifugal element, each cam mechanism converts the centrifugal force into a circumferential force directed to reduce the relative displacement. Support portions are provided on either the rotor or the mass body, and each makes contact with part of each centrifugal element when each centrifugal element receives the rotational moment of inertia. Each support portion supports each centrifugal element such that each centrifugal element is movable in the radial direction.
    Type: Application
    Filed: September 4, 2018
    Publication date: March 21, 2019
    Inventors: Yuki KAWAHARA, Yusuke TOMITA
  • Publication number: 20190085935
    Abstract: A damper device is capable of attenuating fluctuations in torque. The damper device includes a first rotor and a second rotor rotatable relatively to the first rotor. The damper device also includes a plurality of elastic members elastically coupling the first rotor and the second rotor. The second rotor is rotatable relatively to the first rotor while held by the first rotor with use of the plurality of elastic members.
    Type: Application
    Filed: September 14, 2016
    Publication date: March 21, 2019
    Inventor: Yusuke TOMITA
  • Publication number: 20190063549
    Abstract: A torque fluctuation inhibiting device includes a mass body. The mass body disposed to be rotatable with a rotor and be rotatable relatively to the rotor. Each of a plurality of centrifugal elements is radially movable by a centrifugal force that acts thereon in rotation of the rotor and the mass body. When a relative displacement is produced between the rotor and the mass body in a rotational direction while the centrifugal force is acting on the each of the plurality of centrifugal elements, each of a plurality of cam mechanisms converts the centrifugal force into a circumferential force directed to reduce the relative displacement. A plurality of restriction members allow the plurality of centrifugal elements to move in actuation of the plurality of cam mechanisms, and restrict the plurality of centrifugal elements from moving radially inward in non-actuation of the plurality of cam mechanisms.
    Type: Application
    Filed: August 7, 2018
    Publication date: February 28, 2019
    Inventors: Yusuke TOMITA, Keisuke SAKAI
  • Publication number: 20190060433
    Abstract: Isolated KIF20A-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce KIF20A-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.
    Type: Application
    Filed: November 5, 2018
    Publication date: February 28, 2019
    Applicant: OncoTherapy Science, Inc.
    Inventors: Yasuharu Nishimura, Yusuke Tomita, Ryuji Osawa
  • Patent number: 10206989
    Abstract: Isolated CDCA1-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce CDCA1-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: February 19, 2019
    Assignee: OncoTherapy Science, Inc.
    Inventors: Yasuharu Nishimura, Yusuke Tomita, Ryuji Osawa
  • Patent number: 10172926
    Abstract: Isolated KIF20A-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce KIF20A-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: January 8, 2019
    Assignee: OncoTherapy Science, Inc.
    Inventors: Yasuharu Nishimura, Yusuke Tomita, Ryuji Osawa
  • Publication number: 20180117135
    Abstract: Isolated CDCA1-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce CDCA1-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.
    Type: Application
    Filed: January 20, 2017
    Publication date: May 3, 2018
    Inventors: YASUHARU NISHIMURA, YUSUKE TOMITA, RYUJI OSAWA
  • Publication number: 20180000915
    Abstract: Isolated IMP-3-derived epitope peptides having Th1 cell inducibility are disclosed herein. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce IMP-3-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.
    Type: Application
    Filed: August 31, 2017
    Publication date: January 4, 2018
    Inventors: Yasuharu Nishimura, Yusuke Tomita, Masatoshi Hirayama, Ryuji Osawa
  • Publication number: 20170362287
    Abstract: Isolated GPC3-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce GPC3-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors including, for example, hepatocellular carcinoma and melanoma.
    Type: Application
    Filed: December 4, 2015
    Publication date: December 21, 2017
    Applicant: ONCOTHERAPY SCIENCE, INC.
    Inventors: YASUHARU NISHIMURA, YUSUKE TOMITA, RYUJI OSAWA
  • Patent number: 9796015
    Abstract: According to the invention, by setting the linear thermal expansion amount when a mold made of a molding sand is heated from a room temperature to 1000° C. to be not more than 0.9%, and the ratio (D/d) between the diameter of a slump (D) and the diameter of a slump cone (d) in a slump test of the molding sand having a hardening agent kneaded to be not less than 1.65, a molding sand preferable for use in a mold produced using the self-hardening type of three dimensional laminate molding sand mold, having low thermal expansibility preventing occurrence of a veining defect, and capable of forming a large and complicated shape can be obtained.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: October 24, 2017
    Assignee: Kimura Chuzosho Co., Ltd.
    Inventors: Yoya Fukuda, Kenichi Hayashi, Takashi Komai, Yusuke Urushibata, Yusuke Tomita
  • Patent number: 9770498
    Abstract: Isolated IMP-3-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. The peptides of the present invention can promiscuously bind to MHC class II molecules and induce IMP-3-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors expressing IMP-3.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: September 26, 2017
    Assignee: OncoTherapy Science, Inc.
    Inventors: Yasuharu Nishimura, Yusuke Tomita, Masatoshi Hirayama, Ryuji Osawa
  • Publication number: 20170224795
    Abstract: Isolated CDCA1-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce CDCA1-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.
    Type: Application
    Filed: January 20, 2017
    Publication date: August 10, 2017
    Inventors: YASUHARU NISHIMURA, YUSUKE TOMITA, RYUJI OSAWA